Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | NMT1 | P30419 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CLK1 | P49759 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18285428 | 0.93 | MAPT (0.47) | MAPTALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL29896345 | 0.93 | MAPT (0.47) | MAPTALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL31603107 | 0.90 | MAPT (0.63) | MAPTALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL620359 | 0.90 | MAPT (0.63) | MAPTALDH1A1SMN1; SMN2KDM4ELMNA | |
| Butane SCHEMBL3825261 | 0.88 | MAPT (0.61) | MAPTALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL1983426 | 0.86 | TP53 (0.55) | MAPTALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL1467397 | 0.86 | KMT2A (0.54) | MAPTALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL29208291 | 0.86 | MAPT (0.53) | MAPTALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL30855071 | 0.85 | MAPT (0.61) | MAPTALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL5767699 | 0.85 | MAPK1 (0.55) | MAPTALDH1A1SMN1; SMN2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427582-B2 | Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use | UWM RESEARCH FOUNDATION, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| EP-3565807-B1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2021-09-22 | — | — | EP | disclosed |
| US-20210047322-A1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-02-18 | — | — | US | disclosed |
| US-10865203-B2 | Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use | UWM RESEARCH FOUNDATION, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| EP-3325479-B1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE | UWM RES FOUNDATION INC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-10669266-B2 | Oxadiazole inhibitors of HIPK2 for treating kidney fibrosis | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-06-02 | — | — | US | disclosed |
| WO-2020071550-A1 | CDK8 INHIBITOR AND USE OF SAME | 京都薬品工業株式会社 | 2020-04-09 | — | — | WO | disclosed |
| US-20190352292-A1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-11-21 | — | — | US | disclosed |
| EP-3565807-A1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | Icahn School of Medicine at Mount Sinai (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-2970125-B1 | SUBSTITUTED NAPHTHYRIDINE AND QUINOLINE COMPOUNDS AS MAO INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2018-07-18 | — | — | EP | disclosed |
| EP-1042295-A1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-10-11 | — | — | EP | disclosed |
| US-6110929-A | IMMUNOMODULATORS WHICH INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR AND INHIBIT T-HELPER-TYPE 2 IMMUNE RESPONSE; FOR TREATMENT OF VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-08-29 | — | — | US | disclosed |
| US-6093732-A | PREVENT HERPESVIRAL INFECTIONS, PARTICULARLY, HUMAN CYTOMEGALOVIRAL INFECTION | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-25 | — | — | US | disclosed |
| WO-2000006577-A1 | OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-1999032450-A1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| US-5773449-A | BACTERICIDES FOR HELICOBACTER | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1998-06-30 | — | — | US | disclosed |
| EP-0786454-A1 | THIOQUINOLONE DERIVATIVE | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 1997-07-30 | — | — | EP | disclosed |
| US-4450167-A | TRANQUILIZERS; PSYCHOLOGICAL DISORDERS | ROUSSEL UCLAF (FR) | 1984-05-22 | — | — | US | disclosed |
| US-4450166-A | N-(4,5-Dihydro-thiazol-2-yl)-3-quinoline-carboxamides having anxiolytic activity | ROUSSEL UCLAF (FR) | 1984-05-22 | — | — | US | disclosed |
| US-4343804-A | 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds | A. H. ROBINS COMPANY, INC. (US) | 1982-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047322-A1 | LIGANDS SELECTIVE TO ALPHA 6 SUBUNIT-CONTAINING GABAA RECEPTORS AND THEIR METHODS OF USE | GABRA6, HTR6, GABRD | MAPT 1631/4885ALDH1A1 647/4885SMN1; SMN2 1894/4885 |
| US-20190352292-A1 | OXADIAZOLE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS | HIPK2, HIPK3, HIPK1 | MAPT 3945/4885ALDH1A1 3645/4885SMN1; SMN2 4343/4885 |
| US-11427582-B2 | Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use | GABRA6, HTR6, GABRD | MAPT 1631/4885ALDH1A1 647/4885SMN1; SMN2 1894/4885 |
| US-10669266-B2 | Oxadiazole inhibitors of HIPK2 for treating kidney fibrosis | HIPK2, HIPK3, HIPK1 | MAPT 3945/4885ALDH1A1 3645/4885SMN1; SMN2 4343/4885 |
| US-10865203-B2 | Ligands selective to alpha 6 subunit-containing GABAA receptors and their methods of use | GABRA6, HTR6, GABRD | MAPT 1874/4885ALDH1A1 604/4885SMN1; SMN2 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.